31 results about "Immunologic Technique" patented technology

The invention belongs to the technical field of immunology, and discloses a manganese salt adjuvant system based on dextran particle capsule shrinkage and a preparation method and application thereof.The manganese salt adjuvant system comprises beta-dextran particles GPs of a hollow spherical shell structure from yeast and manganese hydroxide colloid encapsulated in the dextran particles, the preparation method comprises the following steps: soaking the GPs in a MnCl2 solution, after the inner cavity of the GPs fully absorbs the MnCl2 solution, separating the GPs adsorbing MnCl2, then adding the GPs into a NaOH solution, forming stable manganese hydroxide colloid by manganese ions in the inner cavity of the GPs, and washing after separation to obtain the dextran particle encapsulated manganese salt adjuvant system. The GPMnOH particles carry various antigens at the same time in various modes such as electrostatic adsorption, chemical coupling or hydrophobic interaction, and an ideal carrier is provided for co-delivery immunization of the antigens and adjuvants.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The application discloses a monoclonal antibody of SARS-CoV-2 N protein and a preparation method and application of a test strip thereof. The red microsphere immunochromatography test strip prepared from the monoclonal antibody of SARS-CoV-2 N protein can quickly and accurately detect SARS-CoV-2 N protein, shortens the detection time, simplifies the detection steps, has the characteristics of being quick and convenient and being suitable for on-site detection, and provides a reliable immunological technology for quickly and efficiently detecting SARS-CoV-2 infection.

The invention belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting PD-L1 cross binding of human and cynomolgus monkeys and application of the single-domain antibody. The single-domain antibody disclosed by the invention has the specificity of resisting PD-L1 of human and cynomolgus monkeys, and shows relatively strong binding efficacy in the binding detection of PD-L1 target protein or PD-L1 overexpression cells; in the detection of blocking PD-1 / PD-L1 functions, a part of the single-domain antibodies even show a blocking effect which is obviously superior to that of Atezolizumab, so that the single-domain antibodies prepared by the invention can be used for diagnosis, treatment and prognosis detection of PD-L1 positive tumors. Meanwhile, the single-domain antibody disclosed by the invention has cross-species cross binding capacity, can be directly used for preclinical pharmacodynamics and safety evaluation, does not need to develop a species-specific substitution antibody, and realizes'one target and double effects'.

The invention provides a fully humanized monoclonal antibody for resisting SARS-CoV and SARS-CoV-2 and application of the fully humanized monoclonal antibody, and belongs to the technical field of immunology, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 1; the amino acid sequence of a light chain variable region of the monoclonal antibody SARS2-1 is as shown in SEQ ID NO: 2; the antibody has a unique CDR partition, can identify S proteins of the two viruses at the same time, and has cross-neutralization activity on pseudoviruses of the two viruses. The antibody has the characteristics of high expression, full human source and good stability, is suitable for industrial production, and has potential application value for coping with outbreak prevalence caused by coronavirus possibly occurring at present and in the future.

The present application relates to the technical field of immunology, and particularly relates to a murine IgG monoclonal antibody, a preparation method and application thereof. The heavy chain variable region of the monoclonal antibody has an amino acid sequence as shown in SEQ ID NO:1; and the light chain variable region has an amino acid sequence as shown in SEQ ID NO:2. The present application further discloses a DNA molecule encoding the antibody, expression of the antibody, and a eukaryotic host cell transformed by the expression vector. The murine IgG monoclonal antibody provided by the present application is preliminarily verified in a 5L bioreactor, and the expression amount is 5.33g / L. It is identified that the monoclonal antibody is used as a blocking agent for evaluation, and the blocking effect is obvious, and plays an important role in the use of blocking agents.

The invention belongs to the technical field of immunology, and discloses an anti-human CD19 receptor single-domain antibody, and the amino acid sequence of the single-domain antibody is as shown in SEQ ID No.1. The antibody has good reaction activity with human CD19, can be used for detecting or diagnosing CD19 and treating related diseases with abnormal CD19 expression, and has wide application prospects in the fields of drug application, clinical detection and diagnosis and the like.

The invention belongs to the technical field of experimental animal models, biomedical research and immunology, and discloses a photocoagulation thymus ischemia animal model, a method and application of the photocoagulation thymus ischemia animal model in rapid simulation of thymus degeneration and immune senescence, and the model shows at least one or more characteristics 1-7 days after induction: thymus atrophy, thymus weight or thymus index is significantly reduced; the cortical-medullary structure of thymus is disordered or disappears; the expression distribution of the Keratin 5 / Keratin 8 is abnormal; thymic cell apoptosis is increased, and lipid deposition is enhanced; the proportion of CD4 + CD8 + double positive T cells is reduced, and the proportion of DN2 / DN3 stage T cells is increased; the initial T cell output is reduced; and the immune function is reduced. The pathological mechanism is clear; the modeling period is short, and the immune senescence phenotype can be stably obtained within several days; the injury focus is controllable, and systemic stress or hormone interference is avoided; the model has high repeatability and is suitable for mechanism research and drug screening.

The application provides a target RBD anti-Omicron fully human monoclonal antibody 9C4 and application thereof, and belongs to the technical field of microbiology and immunology. The monoclonal antibody 9C4 comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of three complementarity determining regions of the heavy chain variable region are GYAFTTYG, ISTYNGNT and ATSLGLWFGQNS respectively, and the amino acid sequences of three complementarity determining regions of the light chain variable region are SGSIASNY, EDN and QTYDGSNQV respectively. The monoclonal antibody 9C4 provided by the application has high-efficiency, specific anti-Omicron neutralization activity, is fully human, has good stability, and has great application potential in the preparation of a novel coronavirus detection product or a drug for preventing and treating a novel coronavirus disease.

This invention provides a fully human anti-H3N2 virus neutralizing antibody IAV-3 and its applications, belonging to the fields of microbiology and immunology. The amino acid sequence of the heavy chain variable region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:2; the amino acid sequence of the heavy chain constant region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:3, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO:4. The neutralizing antibody provided by this invention has the characteristics of high expression, fully human origin, and good stability, making it suitable for industrial production and possessing potential application value in responding to current and future influenza caused by the H3N2 virus.

The application provides a target RBD anti-Omicron fully human monoclonal antibody 3G5 and an application thereof, and belongs to the technical field of microbiology and immunology. The monoclonal antibody 3G5 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining regions, and the amino acid sequences of the three complementary determining regions are GGS I SS SS NF, I YY SG ST and ARL DLGGDIVVPPAAKPYYYMDV respectively; the light chain variable region has three complementary determining regions, and the amino acid sequences of the three complementary determining regions are SSNIGAGYN, GDI and QSYDSSLSGLYV respectively. The monoclonal antibody 3G5 provided by the application has high-efficiency and specific anti-Omicron neutralization activity, is fully human and has good stability, and has great application potential in the preparation of a novel coronavirus detection product or a drug for preventing and treating a novel coronavirus disease.

The application provides an avian PCV3 gene and application thereof, and belongs to the technical field of animal virology and immunology. The application provides an avian PCV3 gene for the first time, which is named aPCV3, and the nucleotide sequence of the aPCV3 gene comprises any one of SEQ ID NO. 1-2 or a sequence with a homology of more than 90% with SEQ ID NO. 1 and 2. The virus strain containing the aPCV3 gene has a high virus titer and can be stably passaged for multiple times. The inactivated vaccine prepared from the virus strain containing the aPCV3 gene and the subunit vaccine prepared from the Cap gene or the Rep gene in the aPCV3 gene have a significant protective effect on poultry such as chickens, ducks and geese. The ELISA detection plate prepared from the Cap gene or the Rep gene in the aPCV3 gene can accurately detect PCV3 and has high specificity and repeatability.

The invention provides a chicken Marek's virus (MHC) II type molecule restriction epitope peptide, a gene, a primer group, a screening method and application, and belongs to the technical field of immunology. The restrictive epitope peptide of the II-type molecule BLB2 * 21 of the chicken Marek's virus MHC is obtained through AF3 structure prediction and screening, the deviation of traditional bioinformatics prediction is avoided, and the binding activity of the epitope peptide is guaranteed through accurate structure analysis and crystallization verification; the gene for coding the chicken Marek's virus MHC II type molecule restrictive epitope peptide can be used for preparing Marek's virus epitope vaccines and T cell activators, or can be used as a detection target for evaluating the immune state of chicken flocks, and technical support is provided for Marek's disease prevention and control, disease resistance breeding and novel vaccine research and development.

The invention relates to the technical field of cytobiology and immunology, and discloses a cell molecule activation method based on an aqueous two-phase system, which comprises the following steps: preparing the aqueous two-phase system with the concentration of 2-15wt%; adding a suspension containing target cell molecules into the aqueous two-phase system, performing centrifugal separation, and concentrating the target cell molecules; and adding an exogenous signal molecule into the concentrated target cell molecule to activate the target cell molecule. The method has a wide application prospect in the fields of cell therapy, regenerative medicine, tumor immunotherapy and the like. By rapidly activating and enhancing cell functions, the effect of cell therapy can be improved, and a new method is provided for personalized medical treatment and immunotherapy.

This invention discloses a PRRSV NADC30 lineage vaccine, its preparation method, and its applications, belonging to the field of immunology technology. The recombinant chimpanzee adenovirus vector is obtained by introducing the encoding gene of GP35 fusion protein or M-GP5 fusion protein into an expression vector; wherein, the GP35 fusion protein is constructed by linking GP3 and GP5 proteins with a flexible linker peptide; the M-GP5 fusion protein is constructed by linking M and GP5 proteins with a flexible linker peptide. The PRRSV NADC30 lineage vaccine of this invention achieves protection against PRRSV infection by inducing antigen-specific antibodies, neutralizing antibodies, Th1-type cellular immune responses, and / or lymphocyte proliferation reactions. This invention provides a promising candidate antigen and a highly efficient vaccine platform for developing novel recombinant chimpanzee adenovirus vector vaccines against currently circulating NADC30-like strains.

The application discloses an indirect ELISA kit for rapidly detecting porcine epidemic diarrhea virus IgA antibody and application thereof and belongs to the technical field of immunology. The application provides a recombinant PEDV-RBD protein, and an amino acid sequence of the recombinant PEDV-RBD protein is shown as SEQ ID NO. 3. The application constructs an indirect ELISA kit for detecting porcine epidemic diarrhea virus IgA antibody based on the recombinant PEDV-RBD protein, can accurately capture PEDV IgA antibody in sow milk or serum to realize detection, has the advantages of high sensitivity and strong specificity, and provides a technical means for prevention and control of porcine epidemic diarrhea.

This invention belongs to the fields of molecular virology and immunology, and provides an alpaca-derived nanobody that specifically binds to Chikungunya virus (CHIKV), its preparation method, and its applications. The nanobody has a heavy chain variable region (VHH), which comprises the following CDRs: CDR1 (amino acid sequence as shown in SEQ ID NO:1), CDR2 (amino acid sequence as shown in SEQ ID NO:2), and CDR3 (amino acid sequence as shown in SEQ ID NO:3). The VHH includes four frame regions FR1-FR4; FR1, FR2, FR3, and FR4 are arranged alternately with CDR1, CDR2, and CDR3 in sequence. The nanobody of this invention can efficiently neutralize CHIKV virus and inhibit its infection, and has the potential to prepare drugs or kits for the prevention, treatment, and / or detection of CHIKV infection. The nanobody of this invention can bind with high affinity to the E protein of CHIKV, effectively inhibiting CHIKV pseudovirus infection.

The invention discloses a novel anti-echinococcus monoclonal antibody, a hybridoma cell strain and application of the novel anti-echinococcus monoclonal antibody, and belongs to the technical field of biomedicine and immunology. The preservation number of the hybridoma cell strain Anti-Em-11 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 46598. According to the present invention, the specific monoclonal antibody is successfully prepared and identified, and Western blot and indirect immunofluorescence experiments prove that the obtained monoclonal antibody has high specificity on the recombinant protein. The invention lays a solid foundation for serological diagnosis of the echinococcosis and remarkably enriches the existing serological detection technical system.

The present application belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting human and cynomolgus monkey PD-L1 cross-binding and application thereof. The single-domain antibody has specificity against human and cynomolgus monkey PD-L1, and shows strong binding efficiency in the binding detection with a PD-L1 target protein or a PD-L1 overexpression cell. In the detection of blocking PD-1 / PD-L1 function, part of the single-domain antibodies even show a blocking effect significantly better than Atezolizumab, which confirms that the single-domain antibody prepared by the present application can be used for the diagnosis, treatment and prognosis detection of PD-L1 positive tumors. Meanwhile, the single-domain antibody has cross-binding ability across species, and can be directly used for preclinical pharmacodynamics and safety evaluation, without the need to develop species-specific alternative antibodies, so as to achieve "one target with double effect".

The application provides a kind of anti-SARS-CoV and SARS-CoV-2 fully human monoclonal antibody and its application, belong to immunology technical field, the amino acid sequence of the variable region of heavy chain of the monoclonal antibody is as shown in SEQ ID NO:1;The amino acid sequence of the variable region of light chain of the monoclonal antibody SARS2-1 is as shown in SEQ ID NO:2;The antibody has unique CDR partition, can simultaneously recognize the S protein of the two viruses mentioned above, and has cross-neutralizing activity to the pseudo virus of the two viruses mentioned above.The antibody has the characteristics of high expression, fully human, good stability at the same time, is suitable for industrial production, has potential application value for coping with the outbreak and prevalence caused by coronavirus at present and in the future.

The invention relates to the technical field of molecular biology and immunology, in particular to a bovine herpesvirus type 4 gb protein recombinant expression method and application thereof.The 104-384aa segment (the amino acid sequence is shown as SEQ ID NO.2) of bovine herpesvirus type 4 gb protein is selected and constructed to a pet22b / pet32a escherichia coli expression vector, after induced culture and ultrasonication, Ni-NTA gradient elution purification is conducted, and the recombinant expression vector is obtained. The recombinant gb protein with the molecular weight of about 48.5 kDa is obtained. The recombinant protein is used for preparing mouse antiserum, and the titer of the antiserum is not lower than 1: 128000 through ELISA (enzyme-linked immuno sorbent assay) detection; the purity of the purified antiserum meets experimental requirements, and the antiserum can specifically recognize a target antigen. The method solves the problems of poor protein dissolution and low antiserum titer in the traditional method, is controllable in process and high in cost effectiveness, and provides a reliable tool for molecular detection and immunoassay of the bovine herpesvirus type 4.

The application belongs to the technical field of immunology, and particularly relates to an anti-membrane immunoglobulin T (mIgT) monoclonal antibody of Siniperca duensis, and a preparation method and application thereof. The application provides a hybridoma cell strain 4D7 capable of secreting an anti-membrane immunoglobulin T (mIgT) monoclonal antibody or an antigen binding fragment thereof for the first time, and the hybridoma cell strain 4D7 is preserved in the China Center for Type Culture Collection on May 13, 2025, with a preservation number of CCTCC NO: C2025160. The anti-membrane IgT monoclonal antibody or the antigen binding fragment thereof provided in the application can specifically react with membrane IgT on the surface of B cells of Siniperca duensis, and can be applied to detecting IgT + B cell surface markers.

The application discloses a nanobody targeting human CD3 and a preparation method and application thereof, relates to the technical field of biological medicine immunology, and the CD3 nanobody is obtained through alpaca immunization, phage library construction and panning, high-efficiency expression and activity verification, has the characteristics of high expression (up to 392 mg / L) and high purity (>95%), can be specifically combined with a human CD3 molecule and a human T cell, and can effectively activate the human T cell (up-regulate CD69 and CD25 molecule expression). The CD3 nanobody of the application overcomes defects of a traditional CD3 antibody, such as large molecular weight and potential immunogenicity risk, can be used as a T cell activator in the fields of immunotherapy drug research and development, tumor immunotherapy, autoimmune disease treatment and the like, and has a wide clinical application prospect.

The application discloses a fluorine-nitrogen modified high-molecular immunoadjuvant material, a preparation method and application thereof, and belongs to the technical field of high-molecular materials and immunology, wherein the high-molecular immunoadjuvant material comprises a biodegradable polycarbonate main chain, and polyethylene glycol segments, perfluoroalkyl side chains and nitrogen-containing seven-membered ring side chains connected to the polycarbonate main chain. The perfluoroalkyl side chains are introduced to promote antigen delivery and improve the antigen presenting cell uptake efficiency; the nitrogen-containing seven-membered ring side chains are introduced to the side chains to make the material have intracellular environment response characteristics, so that the antigen intracellular release process is improved and the antigen utilization efficiency is improved. In addition, the polycarbonate which can be completely degraded by enzymes in the body is used as the main chain framework, so that the material has good delivery performance and biological safety.

The application provides an immunogenicity-based antigen peptide screening method and evaluation method, and belongs to the technical field of immunology.The application provides an evaluation method for candidate antigen peptides screened by a conventional machine algorithm, wherein the candidate antigen peptides are evaluated by polypeptide MHC binding affinity difference, immunogenicity calculation, probability of the candidate antigen peptide-MHC complex being recognized by a TCR, and antigen transporter (TAP) transport efficiency, proteasome cleavage and expression abundance.The application also provides an antigen peptide screening method, which comprises machine algorithm prediction, the above evaluation, ELISpot verification, IFN gamma flow sorting and co-culture with an organoid model, and finally embedding sectioning and Ki-67 immunohistochemical staining to screen immunogenic antigen peptides.The above screening will help to more accurately screen strong immunogenic neoantigen peptides.

The invention belongs to the technical field of immunology, and discloses a single-domain antibody targeting CD28 molecules and application, and the amino acid sequence of the single-domain antibody is as shown in SEQ ID No.1. The antibody has good reaction activity with human CD28, can be used for detecting or diagnosing CD28 and treating related diseases with abnormal CD28 expression, provides a basis for research and development of CD28-targeted drugs, and has very wide prospects and important significance in the fields of drug application, clinical detection and diagnosis and the like.

The application provides an immune cell activity evaluation method, and belongs to the technical field of immunology. The method carries out pre-stimulation on immune cells by using a cytokine mixed solution containing IL-6 and TNF-α, and then carries out co-culture of the pretreated peripheral blood and a logarithmic growth phase target cell suspension, carries out staining and dark incubation, and then carries out detection by using a flow cytometer to calculate the target cell apoptosis ratio. Meanwhile, the mononuclear cells are separated and induced into immune effector cells and are expanded and cultured, the fluorescently labeled target cells are co-incubated with the immune effector cells, and then the killing rate of the immune effector cells on the target cells is calculated. On this basis, the target cell suspension and the immune cell suspension are mixed and incubated according to the effector-target ratio, PI staining solution is added for incubation, and finally the flow cytometer is used to detect the target cell apoptosis rate. Compared with the prior art, the sensitivity of the application is significantly improved, the results have strong comparability, the detection and evaluation process is simple and efficient, and there is no safety risk.

This invention relates to the field of immunology, specifically disclosing an anti-Tau monoclonal antibody and its applications. The heavy chain has three CDR regions with amino acid sequences as shown in SEQ ID NO:1, 2, and 3, respectively; and the light chain has three CDR regions with amino acid sequences as shown in SEQ ID NO:4, 5, and 6, respectively. The anti-Tau monoclonal antibody provided by this invention can bind to the N-terminal projection region of Tau protein, specifically recognizing the N-terminal Thr95 / Thr101 phosphorylation modification site of Tau protein. It can be used for immunoblotting detection of Tau protein and its pathologically related components in human brain samples, for histological detection of Tau pathological structures in transgenic animal and human brain tissue samples, and for pathological staging studies of Tau protein-related diseases.

The present application belongs to the technical field of immunology, and particularly relates to a polypeptide inhibiting neuraminidase 2 activity from sclerotium of poria cocos and a preparation method. The polypeptide monomer shown in the sequence table SEQ ID NO. 1 is extracted from an enzymatic polypeptide solution through an alkaline protease cutting process; and a neuraminidase inhibitor screening kit is used to test the inhibitory activity of each component of the alkaline protease cutting polypeptide of poria cocos on the enzyme, and the results show that the above polypeptide monomer can effectively inhibit the activity of influenza virus neuraminidase 2.

The invention relates to the technical field of biological product science and immunology, in particular to a haemophilus parasuis outer membrane vesicle vaccine, a preparation method and application thereof.The haemophilus parasuis H0014LV5 is preserved in the China Center for Type Culture Collection on November 10, 2025, the preservation number is CCTCC M 20252517, the haemophilus parasuis H0014LV5 secretes outer membrane vesicles, and the haemophilus parasuis H0014LV5 is preserved in the China Center for Type Culture Collection on November 10, 2025. The outer membrane vesicle vaccine is rich in immunogenic protein and immunomodulatory protein, the prepared outer membrane vesicle vaccine is good in immunogenicity, a body can be induced to generate remarkable mucosal immunity through nasal mucosal immunity, meanwhile, remarkable cellular immunity and humoral immunity response are induced, the safety and toxicity dispersing risk existing in attenuated vaccines is overcome, and the vaccine is safe and reliable. The serum type-5 haemophilus parasuis H0014LV5 strain outer membrane vesicle vaccine is safe, can effectively resist type-5 haemophilus parasuis infection through vaccine immunization, and has a wide application prospect.